Yulia A. Komarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yulia A. Komarova has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Asrar B. Malik
Department of Pharmacology and Regenerative Medicine
8 shared publications Kevin Kruse
Department of Pharmacology and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA
8 shared publicationsFei Huang
Department of Pharmacology and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA
6 shared publicationsShuangping Zhao
Department of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, USA
6 shared publicationsAsrar B. Malik
5 shared publicationsMelissa Geyer
Department of Pharmacology and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA
5 shared publications
Latest Publications
- Open Access
- 18 November 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 375
Therapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury
Acute respiratory distress syndrome (ARDS) is a severe pulmonary disease characterized by acute, noncardiogenic pulmonary edema and hypoxemia leading to respiratory failure. It is induced by a diverse array of etiologies, including recent SARS-CoV-2 infection. The current standard of care for ARDS remains predominantly supportive, underscoring the urgent need for targeted pharmacological interventions. To address this critical gap, we developed an inhibitor of the microtubule accessory factor end-binding protein 3 (EB3), a key mediator of pathological calcium signaling in endothelial cells. During injury, EB3 facilitates inositol 1,4,5-trisphosphate receptor 3 (IP 3 R3) clustering on the endoplasmic reticulum membrane, activating widespread calcium release from intracellular stores and leading to endothelial barrier disruption. Using nuclear magnetic resonance (NMR)-guided approaches, we designed and optimized a synthetic EB3 inhibitor, termed vascular therapeutics (VT)-109, with enhanced physicochemical properties. We evaluated the therapeutic potential of VT-109 across a wide range of preclinical models in which pathogenic insults target epithelial or endothelial barriers. Treatment with VT-109 promptly restored the tissue‒fluid balance in the injured lung by inducing the reannealing of VE-cadherin junctions and restoring the endothelial barrier. In addition to vascular protection, VT-109 improved lung architecture and function, normalized immune responses, and significantly reduced both morbidity and mortality in ARDS models. At the molecular level, VT-109 blocks inflammatory NFAT and NF κ B signaling while concurrently activating FOXM1-dependent endothelial regeneration. These findings support EB3 inhibition as a promising therapeutic strategy for ARDS and highlight VT-109 as a versatile drug candidate capable of addressing the multifaceted pathophysiology of this disease.
- 18 November 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 375
Open AccessTherapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury
Acute respiratory distress syndrome (ARDS) is a severe pulmonary disease characterized by acute, noncardiogenic pulmonary edema and hypoxemia leading to respiratory failure. It is induced by a diverse array of etiologies, including recent SARS-CoV-2 infection. The current standard of care for ARDS remains predominantly supportive, underscoring the urgent need for targeted pharmacological interventions. To address this critical gap, we developed an inhibitor of the microtubule accessory factor end-binding protein 3 (EB3), a key mediator of pathological calcium signaling in endothelial cells. During injury, EB3 facilitates inositol 1,4,5-trisphosphate receptor 3 (IP 3 R3) clustering on the endoplasmic reticulum membrane, activating widespread calcium release from intracellular stores and leading to endothelial barrier disruption. Using nuclear magnetic resonance (NMR)-guided approaches, we designed and optimized a synthetic EB3 inhibitor, termed vascular therapeutics (VT)-109, with enhanced physicochemical properties. We evaluated the therapeutic potential of VT-109 across a wide range of preclinical models in which pathogenic insults target epithelial or endothelial barriers. Treatment with VT-109 promptly restored the tissue‒fluid balance in the injured lung by inducing the reannealing of VE-cadherin junctions and restoring the endothelial barrier. In addition to vascular protection, VT-109 improved lung architecture and function, normalized immune responses, and significantly reduced both morbidity and mortality in ARDS models. At the molecular level, VT-109 blocks inflammatory NFAT and NF κ B signaling while concurrently activating FOXM1-dependent endothelial regeneration. These findings support EB3 inhibition as a promising therapeutic strategy for ARDS and highlight VT-109 as a versatile drug candidate capable of addressing the multifaceted pathophysiology of this disease.
- Open Access
- 10 June 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (6) , 115831
Deficiency in N-cadherin-Akt3 signaling impairs the blood-brain barrier
- 10 June 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (6) , 115831
Open AccessDeficiency in N-cadherin-Akt3 signaling impairs the blood-brain barrier
- Open Access
- 6 April 2025
- Published by Elsevier in Photoacoustics
- Vol. 43, 100713
Photoacoustic microscopy for studying mechano-transduction response in resistance vessels
- 6 April 2025
- Published by Elsevier in Photoacoustics
- Vol. 43, 100713
Open AccessPhotoacoustic microscopy for studying mechano-transduction response in resistance vessels
- Top Cited PapersOpen Access
trans-Endothelial neutrophil migration activates bactericidal function via Piezo1 mechanosensing
Top Cited PapersOpen Accesstrans-Endothelial neutrophil migration activates bactericidal function via Piezo1 mechanosensing
- Open Access
Piezo1 induces endothelial responses to shear stress via soluble adenylyl Cyclase-IP3R2 circuit
- Open Access
- 3 October 2023
- Published by Elsevier in Cell Reports Medicine
- Vol. 4 (10) , 101223
End binding-3 inhibitor activates regenerative program in age-related macular degeneration
- 3 October 2023
- Published by Elsevier in Cell Reports Medicine
- Vol. 4 (10) , 101223
Open AccessEnd binding-3 inhibitor activates regenerative program in age-related macular degeneration
- 1 October 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 69 (4) , 391-403
Targeting EB3–IP3R3 Interface with Cognate Peptide Protects from Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a lung disease characterized by acute onset of noncardiogenic pulmonary edema, hypoxemia, and respiratory insufficiency. The current treatment for ARDS is mainly supportive in nature, providing a critical need for targeted pharmacological management. We addressed this medical problem by developing a pharmacological treatment for pulmonary vascular leakage, a culprit of alveolar damage and lung inflammation. Our novel therapeutic target is the microtubule accessory factor EB3 (end binding protein 3), which contributes to pulmonary vascular leakage by amplifying pathological calcium signaling in endothelial cells in response to inflammatory stimuli. EB3 interacts with IP3R3 (inositol 1,4,5-trisphosphate receptor 3) and orchestrates calcium release from endoplasmic reticulum stores. Here, we designed and tested the therapeutic benefits of a 14-aa peptide named CIPRI (cognate IP3 receptor inhibitor), which disrupted EB3–IP3R3 interaction in vitro and in lungs of mice challenged with endotoxin. Treatment with CIPRI or depletion of IP3R3 in lung microvascular endothelial monolayers mitigated calcium release from endoplasmic reticulum stores and prevented a disassembly of vascular endothelial cadherin junctions in response to the proinflammatory mediator α-thrombin. Furthermore, intravenous administration of CIPRI in mice mitigated inflammation-induced lung injury, blocked pulmonary microvascular leakage, prevented activation of NFAT (nuclear factor of activated T cells) signaling, and reduced production of proinflammatory cytokines in the lung tissue. CIPRI also improved survival of mice from endotoxemia and polymicrobial sepsis. Together, these data demonstrate that targeting EB3–IP3R3 interaction with a cognate peptide is a promising strategy to address hyperpermeability of microvessels in inflammatory lung diseases.
- 1 October 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 69 (4) , 391-403
Targeting EB3–IP3R3 Interface with Cognate Peptide Protects from Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a lung disease characterized by acute onset of noncardiogenic pulmonary edema, hypoxemia, and respiratory insufficiency. The current treatment for ARDS is mainly supportive in nature, providing a critical need for targeted pharmacological management. We addressed this medical problem by developing a pharmacological treatment for pulmonary vascular leakage, a culprit of alveolar damage and lung inflammation. Our novel therapeutic target is the microtubule accessory factor EB3 (end binding protein 3), which contributes to pulmonary vascular leakage by amplifying pathological calcium signaling in endothelial cells in response to inflammatory stimuli. EB3 interacts with IP3R3 (inositol 1,4,5-trisphosphate receptor 3) and orchestrates calcium release from endoplasmic reticulum stores. Here, we designed and tested the therapeutic benefits of a 14-aa peptide named CIPRI (cognate IP3 receptor inhibitor), which disrupted EB3–IP3R3 interaction in vitro and in lungs of mice challenged with endotoxin. Treatment with CIPRI or depletion of IP3R3 in lung microvascular endothelial monolayers mitigated calcium release from endoplasmic reticulum stores and prevented a disassembly of vascular endothelial cadherin junctions in response to the proinflammatory mediator α-thrombin. Furthermore, intravenous administration of CIPRI in mice mitigated inflammation-induced lung injury, blocked pulmonary microvascular leakage, prevented activation of NFAT (nuclear factor of activated T cells) signaling, and reduced production of proinflammatory cytokines in the lung tissue. CIPRI also improved survival of mice from endotoxemia and polymicrobial sepsis. Together, these data demonstrate that targeting EB3–IP3R3 interaction with a cognate peptide is a promising strategy to address hyperpermeability of microvessels in inflammatory lung diseases.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 567
N-cadherin Signaling via PI3Kβ-Akt3 Stabilizes Occludin Tight Junctions in the Blood-Brain Barrier
ID 19653 Poster Board 567 Tight junctions (TJs) seal brain endothelial cells (BECs) to form a restrictive blood-brain barrier (BBB) to selectively control the influx of circulating substances into the central nervous system. Critical to the integrity of BBB are pericytes, cells that physically interact with BECs through Neural (N)-cadherin adhesion. Using brain samples from donors of different ages, we observed a significant loss of N-cadherin junctions in middle-aged patients. This change in N-cadherin was associated with a significant disruption of occludin TJs, suggesting a potential important crosstalk between N-cadherin and TJs. Therefore, to better understand the role of N-cadherin function in the BBB, we generated an inducible, EC-specific knockout of N-cadherin in mice. We demonstrated that mutant mice lacking N-cadherin exhibited greater BBB permeability as well as impairments in TJ ultrastructure. Analyzing different TJ proteins in the microvasculature of the brain cortex, we also found significant disruption of occludin but not claudin TJs in these mutant mice. Furthermore, analysis of occludin kinetics in BEC monolayers lacking N-cadherin adhesion revealed significantly greater internalization rates of occludin from TJs, suggesting that N-cadherin signaling stabilizes occludin TJs. We showed that N-cadherin induces the activation of phosphoinositide 3-kinase (PI3K), leading to Akt phosphorylation. Depletion of PI3K p110β or Akt3, but not other p110 or Akt isoforms, increased occludin internalization from TJs in BECs with intact N-cadherin adhesion. Our data indicate that N-cadherin adhesion activates PI3K p110β-Akt3 signaling in BECs that is essential for the stabilization of occludin TJs to strengthen the BBB.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 567
Open AccessN-cadherin Signaling via PI3Kβ-Akt3 Stabilizes Occludin Tight Junctions in the Blood-Brain Barrier
ID 19653 Poster Board 567 Tight junctions (TJs) seal brain endothelial cells (BECs) to form a restrictive blood-brain barrier (BBB) to selectively control the influx of circulating substances into the central nervous system. Critical to the integrity of BBB are pericytes, cells that physically interact with BECs through Neural (N)-cadherin adhesion. Using brain samples from donors of different ages, we observed a significant loss of N-cadherin junctions in middle-aged patients. This change in N-cadherin was associated with a significant disruption of occludin TJs, suggesting a potential important crosstalk between N-cadherin and TJs. Therefore, to better understand the role of N-cadherin function in the BBB, we generated an inducible, EC-specific knockout of N-cadherin in mice. We demonstrated that mutant mice lacking N-cadherin exhibited greater BBB permeability as well as impairments in TJ ultrastructure. Analyzing different TJ proteins in the microvasculature of the brain cortex, we also found significant disruption of occludin but not claudin TJs in these mutant mice. Furthermore, analysis of occludin kinetics in BEC monolayers lacking N-cadherin adhesion revealed significantly greater internalization rates of occludin from TJs, suggesting that N-cadherin signaling stabilizes occludin TJs. We showed that N-cadherin induces the activation of phosphoinositide 3-kinase (PI3K), leading to Akt phosphorylation. Depletion of PI3K p110β or Akt3, but not other p110 or Akt isoforms, increased occludin internalization from TJs in BECs with intact N-cadherin adhesion. Our data indicate that N-cadherin adhesion activates PI3K p110β-Akt3 signaling in BECs that is essential for the stabilization of occludin TJs to strengthen the BBB.
- Open Access
Piezo1 induces endothelial responses to shear stress via soluble adenylyl Cyclase-IP3R2 circuit
- Open Access
- 15 October 2021
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 220 (12)
Tyrosine phosphorylation of S1PR1 leads to chaperone BiP-mediated import to the endoplasmic reticulum
Cell surface G protein–coupled receptors (GPCRs), upon agonist binding, undergo serine–threonine phosphorylation, leading to either receptor recycling or degradation. Here, we show a new fate of GPCRs, exemplified by ER retention of sphingosine-1-phosphate receptor 1 (S1PR1). We show that S1P phosphorylates S1PR1 on tyrosine residue Y143, which is associated with recruitment of activated BiP from the ER into the cytosol. BiP then interacts with endocytosed Y143-S1PR1 and delivers it into the ER. In contrast to WT-S1PR1, which is recycled and stabilizes the endothelial barrier, phosphomimicking S1PR1 (Y143D-S1PR1) is retained by BiP in the ER and increases cytosolic Ca2+ and disrupts barrier function. Intriguingly, a proinflammatory, but non-GPCR agonist, TNF-α, also triggered barrier-disruptive signaling by promoting S1PR1 phosphorylation on Y143 and its import into ER via BiP. BiP depletion restored Y143D-S1PR1 expression on the endothelial cell surface and rescued canonical receptor functions. Findings identify Y143-phosphorylated S1PR1 as a potential target for prevention of endothelial barrier breakdown under inflammatory conditions.
- 15 October 2021
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 220 (12)
Open AccessTyrosine phosphorylation of S1PR1 leads to chaperone BiP-mediated import to the endoplasmic reticulum
Cell surface G protein–coupled receptors (GPCRs), upon agonist binding, undergo serine–threonine phosphorylation, leading to either receptor recycling or degradation. Here, we show a new fate of GPCRs, exemplified by ER retention of sphingosine-1-phosphate receptor 1 (S1PR1). We show that S1P phosphorylates S1PR1 on tyrosine residue Y143, which is associated with recruitment of activated BiP from the ER into the cytosol. BiP then interacts with endocytosed Y143-S1PR1 and delivers it into the ER. In contrast to WT-S1PR1, which is recycled and stabilizes the endothelial barrier, phosphomimicking S1PR1 (Y143D-S1PR1) is retained by BiP in the ER and increases cytosolic Ca2+ and disrupts barrier function. Intriguingly, a proinflammatory, but non-GPCR agonist, TNF-α, also triggered barrier-disruptive signaling by promoting S1PR1 phosphorylation on Y143 and its import into ER via BiP. BiP depletion restored Y143D-S1PR1 expression on the endothelial cell surface and rescued canonical receptor functions. Findings identify Y143-phosphorylated S1PR1 as a potential target for prevention of endothelial barrier breakdown under inflammatory conditions.